Photo Credit: Oral Science International

COVID-19 COLD & FLU GUARD™ Fight Against the Delta, Beta and Gamma Variants of Concern


Monday, August 30, 2021 8:00:00 AM

New data released today shows that Cold & Flu Guard™ oral/nasal spray is more than 99% effective in-vitro against three of the four deadliest variants of the SARS-CoV-2 virus.

The results from the renowned Utah State University Institute of Antiviral Research in the US confirm that Cold & Flu Guard, is highly active against the Delta (India), Beta (South Africa) and Gamma (Japan/Brazil) variants of SARS-CoV-2.

COLD & FLU GUARD™ was developed for application in the nasal and oral cavity to help protect and reduce exposure to respiratory viruses, including SARS-CoV-2. The product is registered for sale in Europe, Canada and USA, and available online in certain markets.

Global data indicates that vaccines against COVID-19 are highly effective in preventing hospitalisation and death, but that vaccinated individuals can still become infected and shed virus. Complementary interventions, like COLD & FLU GUARD™, could potentially be used to protect and reduce viral load at the primary site of initial infection.

"The findings indicate comparable potency for COLD & FLU GUARD against all three variants of concern compared with original strains of the virus. COLD & FLU GUARD™ can be used as supplementary preventative measures to reduce exposure to infectious droplets and potentially reducing the person-to-person transmission risk in close contact situations. Nasal and oral antisepsis have been recommended as part of a comprehensive plan to reduce the risk of virus transmission" said Dr Michael Glogauer, Chief Science Officer at OSI.

FLAVOBAC™ COLD & FLU GUARD™ is an oral and nasal spray product that forms a barrier to protect and prevent viral infections. It is based on a naturally occurring biochemical that help fight infections. It combats viruses by interfering with their ability to adhere to the oral and nasal mucosa. FLAVOBAC™ COLD & FLU GUARD™ has already been reported to kill "99.8% of the SARS-CoV-2 as well as many other respiratory viruses such as human Coronavirus, Influenza virus, Rhinovirus, and RSV. For more information consult www.coldandfluguard.com

"Many people with diabetes, heart disease, cancer, immunocompromised and those who can't afford to be sick need more protection in addition to vaccine and other public health recommendations. COLD & FLU GUARD™ offers a new option to suppress viral spread by trapping and neutralizing the viral load that has entered the nose and mouth. This new data reinforces that COLD & FLU GUARD™ quickly kills SARS-CoV-2 variants of concern, making it an effective and convenient addition to protect against viruses that enter through the mouth and nose", said Christian Sauvageau, President of OSI.

SOURCE: Oral Science International